Xcel Wealth Management’s Royalty Pharma RPRX Stock Holding History

Xcel Wealth Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,000	Closed	-$205K	–	142
2021 Q2	$205K	Hold	5,000	–	–	0.06%	138
2021 Q1	$218K	Sell	5,000 -200	-4%	-$9.48K	0.08%	120
2020 Q4	$260K	Hold	5,200	–	–	0.11%	108
2020 Q3	$218K	Buy	+5,200	New	+$223K	0.11%	100

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

VCG

Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Xcel Wealth Management's RPRX Position: Q3 2021 in Review

Xcel Wealth Management sold out of Royalty Pharma (RPRX) in Q3 2021, closing a stake of 5,000 shares — an estimated $205K sold.

Xcel Wealth Management first reported a position in RPRX in Q3 2020 and held it in 4 quarters. The position peaked at $260K in Q4 2020. 232 funds tracked by Wall St. Rank hold RPRX as of Q3 2021.

Xcel Wealth Management reported no remaining Royalty Pharma position as of Q3 2021 after selling out during the quarter.
Xcel Wealth Management sold 5,000 Royalty Pharma shares in Q3 2021, an estimated $205K.
Xcel Wealth Management first reported a position in Royalty Pharma in Q3 2020 and held it in 4 quarters.
Xcel Wealth Management's Royalty Pharma position peaked at $260K in Q4 2020.
232 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2021.

Based on Xcel Wealth Management's 13F filing for Q3 2021, filed 21 Oct 2021.